Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive algorithm study for post-treatment control after antiretroviral therapy interruption in early-treated HIV-1
2020-006102-23Phase 4Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Completion of immune-virologic and immune-genetic profiling and statistical analysis. Started Jun 2021; status: active.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-006102-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006102-23.